Fennec Pharmaceuticals Inc. (FRA:RV41)

Market Cap	228.14M
Revenue (ttm)	33.06M
Net Income (ttm)	-5.91M
Shares Out	n/a
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	17.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	6.25
Previous Close	6.30
Day's Range	6.25 - 6.65
52-Week Range	4.30 - 8.25
Beta	n/a
RSI	51.99
Earnings Date	Mar 25, 2026

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RV41

Financial Performance

In 2024, Fennec Pharmaceuticals's revenue was $47.54 million, an increase of 123.69% compared to the previous year's $21.25 million. Losses were -$436,000, -97.28% less than in 2023.

Financial numbers in USD